Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959851 | 0.82 | CYSLTR2 (0.34) | CYSLTR2CYSLTR1TAAR1LIPGTLR8 | |
| SCHEMBL2960666 | 0.80 | CA2 (0.37) | — | |
| SCHEMBL2970945 | 0.79 | TP53 (0.35) | CYSLTR2CYSLTR1LIPGTLR8 | |
| SCHEMBL2961224 | 0.76 | TP53 (0.35) | CYSLTR2CYSLTR1LIPGTLR8 | |
| SCHEMBL2969448 | 0.76 | ALDH1A1 (0.42) | TAAR1KDM1ARCOR1 | |
| SCHEMBL2961808 | 0.74 | BCHE (0.33) | CYSLTR2CYSLTR1LIPG | |
| SCHEMBL2958010 | 0.73 | GID4 (0.37) | KDM1ARCOR1CYP3A4CYP2D6 | |
| SCHEMBL2964782 | 0.73 | KDM1A (0.40) | KDM1ACYP3A4 | |
| SCHEMBL2964685 | 0.72 | HTR2C (0.37) | — | |
| SCHEMBL2969029 | 0.70 | CYSLTR2 (0.35) | CYSLTR2CYSLTR1TAAR1LIPGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2006065809-A2 | HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | CYSLTR2 1369/4885CYSLTR1 1727/4885TAAR1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.